Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
about
Psychosocial interventions for fatigue during cancer treatment with palliative intentDevelopment and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experienceUnrealistic optimism in early-phase oncology trials.Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.Evaluation of patient enrollment in oncology phase I clinical trials.Two concepts of therapeutic optimismExtending clinical equipoise to phase 1 trials involving patients: unresolved problemsEvaluation of an educational program to improve communication with patients about early-phase trial participationAmerican Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.An analysis of common ethical justifications for compassionate use programs for experimental drugsNegotiating decisions during informed consent for pediatric Phase I oncology trialsFatigue and its associated psychosocial factors in cancer patients on active palliative treatment measured over timeResearch participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?Dispositional optimism and therapeutic expectations in early-phase oncology trials.Is Participation in Cancer Phase I Trials Really Therapeutic?Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death.Mindsets, informed consent, and research.Moral justification of Phase 1 oncology trials.Psychosocial interventions for fatigue during cancer treatment with palliative intent.Attitudes toward participating in Phase I clinical trials: an investigation with patient-family-physician triads.How to keep high-risk studies ethical: classifying candidate solutions.Phase 1 oncology trials and informed consent.One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies.The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study.Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.Phase 3 Oncology Clinical Trials in South Africa: Experimentation or Therapeutic Misconception?Studying the lay of the land: views and experiences of professionals in the translational pluripotent stem cell field.Patient information in phase 1 trials: A systematic review.Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.
P2860
Q24186804-AF8ADEE1-793B-4BEF-8117-875B33CB8F90Q33448663-3DFF01AA-5B46-457F-A349-80BD534BB627Q33899157-81A365B2-5EA0-4A8A-996A-05BC3089C237Q34163982-99794DA3-FA71-441E-8599-C6806E099B1BQ34251038-13BC40EB-0296-4BD5-BC37-3F16FC61E70AQ34594562-2C81E2CA-4BF0-4DE2-9B4B-30EC930752D7Q35175474-E8999374-99DC-4A37-B48E-5284827536CFQ35788038-6526C9E8-F4FD-4D85-A5B2-8FB41251BB9DQ35863887-617203F5-0F0E-454D-8A3D-8495F7235F15Q35894574-D4E7ACA7-68D5-4212-AE55-BBC7326E0737Q36167006-77C0D0C1-7D47-4C05-8C43-F34914AA77D3Q36321519-9A9E1E9B-4799-4285-ABAC-A4A12B5E6083Q36510959-172CCB83-0821-4A4B-82B8-F8C717F5D2AFQ36736782-9BBC0FB1-E8F9-44A6-B2BE-4227CEF7C1ADQ36788749-7E76F875-A714-49D7-B44E-2F3A52D6A145Q37660474-BFC98D48-A93A-4B08-B201-56012994D9FCQ37686819-45F66227-3B24-4848-A536-355A11D9FE3CQ37700964-26DA79FD-7340-4E54-91E7-AE6C37B67D26Q38210627-2B725A01-61B4-43C9-A36E-B2D955155DF8Q38679193-31DCC236-650F-441F-A066-F2174A1458B7Q40563636-63F6C643-7B71-4156-A711-88E935A382D8Q42355200-A00ABE69-5562-4861-A6EC-F60FCC0826BCQ44378515-56EFC0DC-A76B-471E-BA52-4FEBB9DF817AQ46119000-39FBA010-005A-47B1-A1C7-51A1C7204C23Q46587807-9DA5266A-DF35-4E2D-B867-357A9B1B8C5CQ47325013-EEDF68FF-B2B7-45A3-9403-A7876C9AD126Q47437860-3A1AE232-1DAA-47A9-8130-F6D06E2912ECQ47879705-A22F5BDC-7598-4F8A-B83E-C7A0F909178EQ48270408-45D62B81-AFD6-44B9-AE8A-19A672D7F051Q52692689-56485FBF-E1FB-4712-A24D-62D545E2F869
P2860
Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Benefit in phase 1 oncology tr ...... r reasonable treatment option?
@en
type
label
Benefit in phase 1 oncology tr ...... r reasonable treatment option?
@en
prefLabel
Benefit in phase 1 oncology tr ...... r reasonable treatment option?
@en
P2860
P356
P1433
P1476
Benefit in phase 1 oncology tr ...... r reasonable treatment option?
@en
P2093
Franklin G Miller
P2860
P304
P356
10.1177/1740774508097576
P50
P577
2008-01-01T00:00:00Z